Resumé
Background:Evidence is conflicting regarding statin use and risk of basal cell (BCC) and squamous cell skin cancer (SCC).Methods:Using Danish nationwide registries, we identified all patients with incident BCC/SCC during 2005-2009 and matched them to population controls. We computed odds ratios (ORs) for BCC and SCC associated with statin use.Results:We identified 38 484 cases of BCC and 3724 cases of SCC. Statin ever use was associated with ORs of 1.09 (CI: 1.06-1.13) for BCC and 1.01 (CI: 0.91-1.11) for SCC.Conclusions:Statin use was not associated with risk of SCC. Residual confounding plausibly explains the marginally increased risk of BCC.British Journal of Cancer advance online publication, 7 October 2014; doi:10.1038/bjc.2014.527 www.bjcancer.com.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | British Journal of Cancer |
| Vol/bind | 112 |
| Sider (fra-til) | 153-156 |
| ISSN | 0007-0920 |
| DOI | |
| Status | Udgivet - 2015 |
Fingeraftryk
Citer dette
}
Statin use and risk of nonmelanoma skin cancer : a nationwide study in Denmark. / Pedersen, Sidsel Arnspang; Pottegård, A; Friis, S; Clemmensen, Ole; Andersen, Klaus Ejner; Hallas, J; Gaist, D; Andersen, Klaus Ejner.
I: British Journal of Cancer, Bind 112, 2015, s. 153-156.Publikation: Bidrag til tidsskrift › Letter › Forskning › peer review
TY - JOUR
T1 - Statin use and risk of nonmelanoma skin cancer
T2 - a nationwide study in Denmark
AU - Pedersen, Sidsel Arnspang
AU - Pottegård, A
AU - Friis, S
AU - Clemmensen, Ole
AU - Andersen, Klaus Ejner
AU - Hallas, J
AU - Gaist, D
AU - Andersen, Klaus Ejner
PY - 2015
Y1 - 2015
N2 - Background:Evidence is conflicting regarding statin use and risk of basal cell (BCC) and squamous cell skin cancer (SCC).Methods:Using Danish nationwide registries, we identified all patients with incident BCC/SCC during 2005-2009 and matched them to population controls. We computed odds ratios (ORs) for BCC and SCC associated with statin use.Results:We identified 38 484 cases of BCC and 3724 cases of SCC. Statin ever use was associated with ORs of 1.09 (CI: 1.06-1.13) for BCC and 1.01 (CI: 0.91-1.11) for SCC.Conclusions:Statin use was not associated with risk of SCC. Residual confounding plausibly explains the marginally increased risk of BCC.British Journal of Cancer advance online publication, 7 October 2014; doi:10.1038/bjc.2014.527 www.bjcancer.com.
AB - Background:Evidence is conflicting regarding statin use and risk of basal cell (BCC) and squamous cell skin cancer (SCC).Methods:Using Danish nationwide registries, we identified all patients with incident BCC/SCC during 2005-2009 and matched them to population controls. We computed odds ratios (ORs) for BCC and SCC associated with statin use.Results:We identified 38 484 cases of BCC and 3724 cases of SCC. Statin ever use was associated with ORs of 1.09 (CI: 1.06-1.13) for BCC and 1.01 (CI: 0.91-1.11) for SCC.Conclusions:Statin use was not associated with risk of SCC. Residual confounding plausibly explains the marginally increased risk of BCC.British Journal of Cancer advance online publication, 7 October 2014; doi:10.1038/bjc.2014.527 www.bjcancer.com.
U2 - 10.1038/bjc.2014.527
DO - 10.1038/bjc.2014.527
M3 - Letter
C2 - 25290087
VL - 112
SP - 153
EP - 156
JO - B J C
JF - B J C
SN - 0007-0920
ER -